Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.40 |
| ▸ | ALOX15B | O15296 | 3/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694139 | 0.83 | NR4A1 (0.41) | ESR2CYP3A4SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL317712 | 0.74 | CHRNB2 (0.36) | FDPSMEN1KMT2A | |
| SCHEMBL1681801 | 0.72 | FPR2 (0.33) | SMN1; SMN2ALDH1A1KMT2APOLB | |
| SCHEMBL5175571 | 0.72 | CYP3A4 (0.43) | L3MBTL1ALOX15BFDPSCYP1A2CYP3A4 | |
| SCHEMBL1681893 | 0.71 | LMNA (0.37) | CYP3A4CYP2C9CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL4296439 | 0.71 | SMN1; SMN2 (0.47) | SMN1; SMN2 | |
| SCHEMBL23956239 | 0.70 | NR3C2 (0.34) | ESR2NR3C2F2F10PRSS1 | |
| SCHEMBL8721211 | 0.69 | CYP3A4 (0.41) | L3MBTL1ALOX15BFDPSCYP1A2CYP3A4 | |
| SCHEMBL3967152 | 0.68 | L3MBTL1 (0.50) | L3MBTL1ALOX15BFDPSCYP1A2CYP3A4 | |
| SCHEMBL20721904 | 0.68 | CYP2C9 (0.40) | L3MBTL1CYP2C9RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111039977-B | Phosphorylylation reagent and application thereof in oligonucleotide synthesis | 广州同隽医药科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-111039977-A | Phosphorylylation reagent and application thereof in oligonucleotide synthesis | 广州同隽医药科技有限公司 | 2020-04-21 | — | — | CN | claimed |
| CN-111039977-B | Phosphorylylation reagent and application thereof in oligonucleotide synthesis | 广州同隽医药科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| EP-2873674-B1 | CHIRAL NUCLEIC ACID ADJUVANT | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| CN-111039977-A | Phosphorylylation reagent and application thereof in oligonucleotide synthesis | 广州同隽医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10322173-B2 | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2019-06-18 | — | — | US | disclosed |
| US-10149905-B2 | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-12-11 | — | — | US | disclosed |
| US-10144933-B2 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-12-04 | — | — | US | disclosed |
| US-9617547-B2 | Chiral nucleic acid adjuvant | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| EP-3095459-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTITUMOR EFFECT AND ANTITUMOR AGENT | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2016-11-23 | — | — | EP | disclosed |
| EP-3095460-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTI-ALLERGIC ACTIVITY, AND ANTI-ALLERGIC AGENT | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2016-11-23 | — | — | EP | disclosed |
| EP-3095461-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING IMMUNITY INDUCTION ACTIVITY, AND IMMUNITY INDUCTION ACTIVATOR | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160333349-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING IMMUNITY INDUCTION ACTIVITY, AND IMMUNITY INDUCTION ACTIVATOR | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160331835-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTI-ALLERGIC ACTIVITY, AND ANTI-ALLERGIC AGENT | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160331836-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTITUMOR EFFECT AND ANTITUMOR AGENT | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20150166999-A1 | CHIRAL NUCLEIC ACID ADJUVANT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2873674-A1 | CHIRAL NUCLEIC ACID ADJUVANT | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166999-A1 | CHIRAL NUCLEIC ACID ADJUVANT | IFNAR1, IFNG, IRF3 | L3MBTL1 2188/4885ALOX15B 1089/4885FDPS 3799/4885 |
| US-20160331836-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTITUMOR EFFECT AND ANTITUMOR AGENT | DDX21, DDX24, TLR9 | L3MBTL1 1417/4885ALOX15B 1638/4885FDPS 3820/4885 |
| US-10149905-B2 | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent | DDX21, DDX24, TLR9 | L3MBTL1 1417/4885ALOX15B 1638/4885FDPS 3820/4885 |
| US-10322173-B2 | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent | TLR9, POLL, MRGPRX2 | L3MBTL1 1392/4885ALOX15B 542/4885FDPS 4433/4885 |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | L3MBTL1 398/4885ALOX15B 3345/4885FDPS 1281/4885 |
| US-10144933-B2 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator | TLR9, IRF3, TLR3 | L3MBTL1 467/4885ALOX15B 1517/4885FDPS 2283/4885 |
| US-20160331835-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTI-ALLERGIC ACTIVITY, AND ANTI-ALLERGIC AGENT | TLR9, MRGPRX2, POLL | L3MBTL1 1982/4885ALOX15B 504/4885FDPS 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.